MX347709B - Proceso para preparar acidos [(3 - hidroxipiridin - 2 - carbonil) amino] alcanoicos, los esteres y amidas. - Google Patents

Proceso para preparar acidos [(3 - hidroxipiridin - 2 - carbonil) amino] alcanoicos, los esteres y amidas.

Info

Publication number
MX347709B
MX347709B MX2015016579A MX2015016579A MX347709B MX 347709 B MX347709 B MX 347709B MX 2015016579 A MX2015016579 A MX 2015016579A MX 2015016579 A MX2015016579 A MX 2015016579A MX 347709 B MX347709 B MX 347709B
Authority
MX
Mexico
Prior art keywords
hydroxypyridine
carbonyl
amino
acids
preparing
Prior art date
Application number
MX2015016579A
Other languages
English (en)
Inventor
M Lanthier Christopher
Gorin Boris
Oudenes Jan
edward dixon Craig
Quigbo Lu Alan
Densmore Copp James
Michael Janusz John
Original Assignee
Akebia Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Akebia Therapeutics Inc filed Critical Akebia Therapeutics Inc
Publication of MX347709B publication Critical patent/MX347709B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/81—Amides; Imides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J31/00—Catalysts comprising hydrides, coordination complexes or organic compounds
    • B01J31/16—Catalysts comprising hydrides, coordination complexes or organic compounds containing coordination complexes
    • B01J31/24—Phosphines, i.e. phosphorus bonded to only carbon atoms, or to both carbon and hydrogen atoms, including e.g. sp2-hybridised phosphorus compounds such as phosphabenzene, phosphole or anionic phospholide ligands
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/79—Acids; Esters
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/79—Acids; Esters
    • C07D213/803—Processes of preparation
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J2531/00—Additional information regarding catalytic systems classified in B01J31/00
    • B01J2531/80—Complexes comprising metals of Group VIII as the central metal
    • B01J2531/82—Metals of the platinum group
    • B01J2531/824—Palladium

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Inorganic Chemistry (AREA)
  • Epidemiology (AREA)
  • Materials Engineering (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Ophthalmology & Optometry (AREA)
  • Cardiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Se describen los procesos para preparar ácidos [(3-hidroxipiridin-2-carbonil)amino] alcanóicos, los derivados, entre otros, los ácidos [(3-hidroxipiridin-2-carbonil)amino}acétic os con sustitución 5-arilo y 5-heteroarilo. Además se describen los métodos para preparar profármacos de los ácidos [(3-hidroxipiridin-2-carbonil)amino]acéticos, por ejemplo, los ésteres de ácido [(3-hidroxipiridin-2-carbonil)amino}acético y las amidas del ácido {[(3-hidroxipiridin-2-carbonil)amino}acético. Los compuestos descritos son útiles como inhibidores de propil hidroxilasa o para tratar estados en donde se desea la inhibición de propil hidroxilasa.
MX2015016579A 2011-06-06 2012-06-05 Proceso para preparar acidos [(3 - hidroxipiridin - 2 - carbonil) amino] alcanoicos, los esteres y amidas. MX347709B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161493536P 2011-06-06 2011-06-06
PCT/US2012/040833 WO2012170377A1 (en) 2011-06-06 2012-06-05 Process for preparing [(3-hydroxypyridine-2-carbonyl)amino]alkanoic acids, esters and amides

Publications (1)

Publication Number Publication Date
MX347709B true MX347709B (es) 2017-05-10

Family

ID=47262177

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2015016579A MX347709B (es) 2011-06-06 2012-06-05 Proceso para preparar acidos [(3 - hidroxipiridin - 2 - carbonil) amino] alcanoicos, los esteres y amidas.
MX2013014228A MX337216B (es) 2011-06-06 2012-06-05 Proceso para preparar acidos [(3-hidroxipiridin-2-carbonil)amino] alcanoicos, los esteres y amidas.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2013014228A MX337216B (es) 2011-06-06 2012-06-05 Proceso para preparar acidos [(3-hidroxipiridin-2-carbonil)amino] alcanoicos, los esteres y amidas.

Country Status (24)

Country Link
US (6) US9145366B2 (es)
EP (5) EP3290404B1 (es)
JP (6) JP6290781B2 (es)
KR (5) KR102059366B1 (es)
CN (1) CN106518759B (es)
AU (4) AU2012268426B2 (es)
CA (2) CA3135440A1 (es)
CY (4) CY1117177T1 (es)
DK (4) DK3290404T3 (es)
ES (4) ES2771232T3 (es)
HK (3) HK1196616A1 (es)
HR (4) HRP20211916T1 (es)
HU (4) HUE048044T2 (es)
IL (1) IL229775A (es)
LT (3) LT3000808T (es)
MX (2) MX347709B (es)
NO (1) NO2686520T3 (es)
PL (4) PL3290404T3 (es)
PT (4) PT3683209T (es)
RS (3) RS54517B1 (es)
RU (2) RU2602083C2 (es)
SI (4) SI3683209T1 (es)
SM (1) SMT201600013B (es)
WO (1) WO2012170377A1 (es)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5113838B2 (ja) 2006-06-26 2013-01-09 アケビア セラピューティックス， インコーポレイテッド プロリルヒドロキシラーゼ阻害剤および使用方法
NO2686520T3 (es) 2011-06-06 2018-03-17
SG11201509998WA (en) * 2013-06-13 2016-01-28 Akebia Therapeutics Inc Compositions and methods for treating anemia
TW201946625A (zh) * 2013-11-15 2019-12-16 美商阿克比治療有限公司 {[5-(3-氯苯基)-3-羥基吡啶-2-羰基]胺基}乙酸之固體型式，其組合物及用途
CA2959688C (en) 2014-09-02 2024-02-27 Sunshine Lake Pharma Co., Ltd. Quinolone compounds and their use to treat diseases related to hypoxia inducible factor and/or erythropoietin
WO2016118858A1 (en) 2015-01-23 2016-07-28 Akebia Therapeutics, Inc. Solid forms of 2-(5-(3-fluorophenyl)-3-hydroxypicolinamido)acetic acid, compositions, and uses thereof
EP3270922A4 (en) * 2015-03-20 2018-08-01 Akebia Therapeutics Inc. Deuterium-enriched hypoxia-inducible factor prolyl hydroxylase enzyme inhibitors
CN106146395B (zh) 2015-03-27 2019-01-01 沈阳三生制药有限责任公司 3-羟基吡啶化合物、其制备方法及其制药用途
DK3277270T3 (da) 2015-04-01 2021-12-06 Akebia Therapeutics Inc Sammensætninger og fremgangsmåder til behandling af anæmi
AU2017376517B2 (en) * 2016-12-13 2021-03-25 Crystal Pharmaceutical (Suzhou) Co., Ltd. Novel crystalline forms of {[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl] amino} acetic acid and processes for preparation thereof
AU2017406103B2 (en) * 2017-03-29 2023-12-14 Emerald Health Pharmaceuticals, Inc. Cannabidiol derivatives as inhibitors of the HIF prolyl hydroxylases activity
WO2019028150A1 (en) 2017-08-01 2019-02-07 Akebia Therapeutics, Inc. COMPOSITIONS FOR USE IN METHODS OF TREATING HEMOGLOBINOPATHIES
CN112088155A (zh) * 2018-05-09 2020-12-15 阿克比治疗有限公司 用于制备2-[[5-(3-氯苯基)-3-羟基吡啶-2-羰基]氨基]乙酸的方法
WO2020075199A1 (en) 2018-10-12 2020-04-16 Mylan Laboratories Limited Polymorphic forms of vadadustat
US11970450B2 (en) 2018-11-28 2024-04-30 Sandoz Ag Multi-component crystals of an orally available HIF prolyl hydroxylase inhibitor
US20220204451A1 (en) 2019-04-26 2022-06-30 Kaneka Corporation Method for producing a vadadustat intermediate
US11524939B2 (en) 2019-11-13 2022-12-13 Akebia Therapeutics, Inc. Solid forms of {[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino} acetic acid
CN111087343B (zh) * 2019-11-29 2022-02-18 万华化学集团股份有限公司 一种羟基吡啶配体及其制备方法和催化应用
WO2021117767A1 (ja) * 2019-12-10 2021-06-17 田辺三菱製薬株式会社 含窒素ヘテロアリールカルボキサミド酢酸誘導体の製造方法
EP4094832A4 (en) 2020-01-24 2024-04-17 Aps Japan Co Ltd PHOTOCATALYST UNIT AND MASK PROVIDED WITH A PHOTOCATALYST UNIT
US20230286918A1 (en) 2020-07-02 2023-09-14 Akebia Therapeutics, Inc. Manufacturing process for 3,5-dichloropicolinonitrile for synthesis of vadadustat
GB202011431D0 (en) * 2020-07-23 2020-09-09 Johnson Matthey Plc Polymorphs of vadadustat and methods for preparing the polymorphs
WO2023111990A1 (en) 2021-12-17 2023-06-22 Akebia Therapeutics, Inc. Selective phd1 inhibitor compounds, compositions, and methods of use

Family Cites Families (111)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3655679A (en) * 1969-06-25 1972-04-11 Merck & Co Inc Certain aryl pyridine carboxylic acid derivatives
US3703582A (en) * 1970-04-20 1972-11-21 Merck & Co Inc Aryl pyridine carboxylic acids in the treatment of inflammation
US3894920A (en) 1971-12-21 1975-07-15 Sagami Chem Res Process for preparing alkyl-substituted 3,6-dihydro-o-dioxin derivatives
US4016287A (en) 1972-07-17 1977-04-05 Boehringer Ingelheim Gmbh Dermatological compositions containing an acylamino-carboxylic acid or an alkyl ester thereof
TW219933B (es) 1990-02-26 1994-02-01 Lilly Co Eli
US5405613A (en) 1991-12-11 1995-04-11 Creative Nutrition Canada Corp. Vitamin/mineral composition
TW352384B (en) 1992-03-24 1999-02-11 Hoechst Ag Sulfonamido- or sulfonamidocarbonylpyridine-2-carboxamides, process for their preparation and their use as pharmaceuticals
DE4219158A1 (de) 1992-06-11 1993-12-16 Thomae Gmbh Dr K Biphenylderivate, diese Verbindungen enthaltende Arzneimittel und Verfahren zu ihrer Herstellung
DE59401923D1 (de) * 1993-11-02 1997-04-10 Hoechst Ag Substituierte heterocyclische Carbonsäureamidester, ihre Herstellung und ihre Verwendung als Arzneimittel
ES2101421T3 (es) 1993-11-02 1997-07-01 Hoechst Ag Amidas de acidos carboxilicos heterociclicos sustituidos, su preparacion y su utilizacion como medicamentos.
NZ270267A (en) 1993-12-30 1997-03-24 Hoechst Ag 3-hydroxypyridin-2yl (and -quinolin-2-yl) carboxamide derivatives and pharmaceutical compositions
DE4410480A1 (de) 1994-03-25 1995-09-28 Hoechst Ag Sulfonamidocarbonylpyridin-2-carbonsäureesteramide sowie ihre Pyridin-N-oxide, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
DE4410423A1 (de) 1994-03-25 1995-09-28 Hoechst Ag Sulfonamidocarbonylpyridin-2-carbonsäureamide sowie ihre Pyridin-N-oxide, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
US5789426A (en) 1995-01-20 1998-08-04 Cornell Research Foundation, Inc. Method for the treatment of fibroproliferative disorders by application of inhibitors of protein hydroxylation
IL135495A (en) 1995-09-28 2002-12-01 Hoechst Ag Intermediate compounds for the preparation of quinoline-converted amines - 2 - carboxylic acid
JPH09221476A (ja) 1995-12-15 1997-08-26 Otsuka Pharmaceut Co Ltd 医薬組成物
AU5762896A (en) 1996-04-30 1997-11-19 Hoechst Aktiengesellschaft 3-alkoxypyridine-2-carboxylic acid amide esters, their preparation and the ir use as drugs
DE19620041A1 (de) 1996-05-17 1998-01-29 Merck Patent Gmbh Adhäsionsrezeptor-Antagonisten
DE19650215A1 (de) 1996-12-04 1998-06-10 Hoechst Ag 3-Hydroxypyridin-2-carbonsäureamidester, ihre Herstellung und ihre Verwendung als Arzneimittel
US6277865B1 (en) 1997-06-27 2001-08-21 Aventis Pharmaceuticals Products Inc. Piperididinyl and N-amidinopiperidinyl derivatives
CN1282319A (zh) 1997-10-09 2001-01-31 小野药品工业株式会社 氨基丁酸衍生物
DE19746287A1 (de) 1997-10-20 1999-04-22 Hoechst Marion Roussel De Gmbh Substituierte Isochinolin-2-Carbonsäureamide, ihre Herstellung und ihre Verwendung als Arzneimittel
US6159379A (en) 1999-05-04 2000-12-12 Baker Hughes Incorporated Organic ammonium salts for the removal of water soluble organics in produced water
JP2001048786A (ja) 1999-08-05 2001-02-20 Yamanouchi Pharmaceut Co Ltd 三環式ヘテロアリール誘導体
US6589758B1 (en) 2000-05-19 2003-07-08 Amgen Inc. Crystal of a kinase-ligand complex and methods of use
US6849718B2 (en) 2001-03-20 2005-02-01 Dana Farber Cancer Institute, Inc. Muteins of hypoxia inducible factor alpha and methods of use thereof
US6855510B2 (en) 2001-03-20 2005-02-15 Dana Farber Cancer Institute, Inc. Pharmaceuticals and methods for treating hypoxia and screening methods therefor
AU2002241154A1 (en) 2001-03-21 2002-10-03 Isis Innovation Ltd. Assays, methods and means relating to hypoxia inducible factor (hif) hydroxylase
SE0101327D0 (sv) 2001-04-12 2001-04-12 Astrazeneca Ab New crystalline forms
US6566088B1 (en) 2001-10-04 2003-05-20 Board Of Regents, The University Of Texas System Prolyl-4-hydroxylases
GB0124941D0 (en) 2001-10-17 2001-12-05 Glaxo Group Ltd Chemical compounds
CA3094774A1 (en) 2001-12-06 2003-07-03 Fibrogen, Inc. Use of hif prolyl hydroxylase inhibitors for treating neurological disorders
EP1556033A4 (en) 2002-05-17 2006-05-31 Celgene Corp METHODS AND COMPOSITIONS USING CYTOKINE INHIBITOR SELECTIVE MEDICAMENTS FOR THE TREATMENT AND MANAGEMENT OF CANCERS AND OTHER DISEASES
EP1545538A2 (en) 2002-08-29 2005-06-29 Merck & Co., Inc. N-biarylmethyl aminocycloalkanecarboxamide derivatives
ES2337043T3 (es) 2002-10-16 2010-04-20 Isis Innovation Limited Metodos de escrutinio empleando un modelo estructural de fih.
CA2506799A1 (en) 2002-11-21 2004-06-10 Eli Lilly And Company Mixed lineage kinase modulators
US8124582B2 (en) 2002-12-06 2012-02-28 Fibrogen, Inc. Treatment of diabetes
US7618940B2 (en) 2002-12-06 2009-11-17 Fibrogen, Inc. Fat regulation
US7183287B2 (en) 2003-04-03 2007-02-27 Pharmacia Corporation Substituted pyrimidinones
US20060251638A1 (en) 2003-06-06 2006-11-09 Volkmar Guenzler-Pukall Cytoprotection through the use of hif hydroxylase inhibitors
JP2006527200A (ja) 2003-06-06 2006-11-30 ファイブロゲン インコーポレイティッド 窒素含有ヘテロアリール化合物および内因性エリトロポエチンを増加させる際のそれらの使用方法
US8614204B2 (en) 2003-06-06 2013-12-24 Fibrogen, Inc. Enhanced erythropoiesis and iron metabolism
GB0314129D0 (en) 2003-06-18 2003-07-23 Astrazeneca Ab Therapeutic agents
WO2005108370A1 (ja) 2004-04-16 2005-11-17 Ajinomoto Co., Inc. ベンゼン化合物
ATE443775T1 (de) 2004-05-28 2009-10-15 Fibrogen Inc Hif-prolylhydroxylase-aktivitätstest
JP2008500951A (ja) 2004-05-31 2008-01-17 田辺三菱製薬株式会社 二環化合物
EP1771169A1 (en) 2004-07-14 2007-04-11 PTC Therapeutics, Inc. Methods for treating hepatitis c
TW200616969A (en) 2004-09-17 2006-06-01 Tanabe Seiyaku Co Imidazole compound
WO2006084210A2 (en) 2005-02-04 2006-08-10 Regents Of The University Of California, San Diego Hif modulating compounds and methods of use thereof
DE102005019712A1 (de) 2005-04-28 2006-11-09 Bayer Healthcare Ag Dipyridyl-dihydropyrazolone und ihre Verwendung
WO2006133391A2 (en) 2005-06-06 2006-12-14 Fibrogen, Inc. Improved treatment for anemia using a hif-alpha stabilising agent
AU2006259352A1 (en) 2005-06-15 2006-12-28 Fibrogen, Inc. Use of HIF 1alfa modulators for treatment of cancer
WO2007033216A2 (en) 2005-09-12 2007-03-22 Beth Israel Deaconess Medical Center Methods and compositions for the treatment and diagnosis of diseases characterized by vascular leak, hypotension, or a procoagulant state
WO2007038571A2 (en) 2005-09-26 2007-04-05 Smithkline Beecham Corporation Prolyl hydroxylase antagonists
US20090176726A1 (en) 2005-10-11 2009-07-09 Fisher David E Methods for treating mitf-related disorders
EP1960363B1 (en) 2005-12-09 2014-01-22 Amgen, Inc. Quinolone based compounds exhibiting prolyl hydroxylase inhibitory activity, compositions and uses thereof
MX2008008608A (es) 2006-01-09 2009-03-04 Btg Int Ltd Moduladores de factor i inducible por hipoxia y usos relacionados.
WO2007082899A1 (en) 2006-01-17 2007-07-26 Vib Vzw Inhibitors of prolyl-hydroxylase 1 for the treatment of skeletal muscle degeneration
TW200738709A (en) 2006-01-19 2007-10-16 Osi Pharm Inc Fused heterobicyclic kinase inhibitors
JP4801451B2 (ja) 2006-01-19 2011-10-26 株式会社日立ハイテクノロジーズ 走査電子顕微鏡等に用いる電子銃の制御装置及び制御方法
ITMI20060179A1 (it) 2006-02-02 2007-08-03 Abiogen Pharma Spa Procedimento per la risoluzione di miscele racemiche e complesso diastereoisomerico di un agente risolvente e di unantiomero di interesse
WO2007101204A1 (en) 2006-02-27 2007-09-07 Alcon Research, Ltd. Method of treating glaucoma
TW200808793A (en) 2006-03-07 2008-02-16 Smithkline Beecham Corp Prolyl hydroxylase inhibitors
US7588924B2 (en) 2006-03-07 2009-09-15 Procter & Gamble Company Crystal of hypoxia inducible factor 1 alpha prolyl hydroxylase
JP2009537558A (ja) 2006-05-16 2009-10-29 スミスクライン・ビーチャム・コーポレイション プロリルヒドロキシラーゼ阻害剤
AR061570A1 (es) 2006-06-23 2008-09-03 Smithkline Beecham Corp Compuesto de glicina sustituido en el n heteroaromatico composicion farmaceutica que lo comprende, su uso para preparar un medicamento, procedimientos para preparar dicha composicion farmaceutica y para preparar el compuesto
JP5113838B2 (ja) 2006-06-26 2013-01-09 アケビア セラピューティックス， インコーポレイテッド プロリルヒドロキシラーゼ阻害剤および使用方法
TW200845994A (en) 2007-01-12 2008-12-01 Smithkline Beecham Corp N-substituted glycine derivatives: prolyl hydroxylase inhibitors
TW200845991A (en) 2007-01-12 2008-12-01 Smithkline Beecham Corp N-substituted glycine derivatives: hydroxylase inhibitors
EP2155680B1 (en) 2007-04-18 2013-12-04 Amgen, Inc Indanone derivatives that inhibit prolyl hydroxylase
AU2008241503A1 (en) 2007-04-18 2008-10-30 Merck Sharp & Dohme Corp. Novel 1,8-naphthyridine compounds
ES2389063T3 (es) 2007-05-04 2012-10-22 Amgen, Inc Derivados de tienopiridina y tiazolopiridina que inhiben la actividad prolil hidroxilasa
EP2160187B1 (en) 2007-05-16 2013-05-22 Merck Sharp & Dohme Corp. Spiroindalones
CN101765596B (zh) 2007-05-18 2015-04-29 拜耳知识产权有限责任公司 用于治疗过增生症状和与血管生成有关疾病的缺氧诱导因子(hif)抑制剂
CN101868251B (zh) 2007-08-06 2012-10-10 千寿制药株式会社 含有HIF-1α和HIF-2α表达抑制物质的药物
TW200908984A (en) 2007-08-07 2009-03-01 Piramal Life Sciences Ltd Pyridyl derivatives, their preparation and use
WO2009037570A2 (en) 2007-08-10 2009-03-26 Crystalgenomics, Inc. Pyridine derivatives and methods of use thereof
WO2009035534A2 (en) 2007-09-07 2009-03-19 The Cleveland Clinic Foundation Treatment of ischemic eye disease by the systematic pharmaceutical activation of hypoxia inducible factor (hif)
WO2009039321A1 (en) 2007-09-19 2009-03-26 Smithkline Beecham Corporation Prolyl hydroxylase inhibitors
WO2009039323A1 (en) 2007-09-19 2009-03-26 Smithkline Beecham Corporation Prolyl hydroxylase inhibitors
WO2009043093A1 (en) 2007-10-04 2009-04-09 Newsouth Innovations Pty Limited Hif inhibition
WO2009049112A1 (en) 2007-10-10 2009-04-16 Smithkline Beecham Corporation Prolyl hydroxylase inhibitors
WO2009067790A1 (en) 2007-11-26 2009-06-04 Uti Limited Partnership STIMULATION OF HYPOXIA INDUCIBLE FACTOR -1 ALPHA (HIF-1α) FOR THE TREATMENT OF CLOSTRIDIUM DIFFICILE ASSOCIATED DISEASE (CDAD), FOR INTESTINAL MOTILITY AND FOR DETECTING INFECTION
WO2009070644A1 (en) 2007-11-30 2009-06-04 Smithkline Beecham Corporation Prolyl hydroxylase inhibitors
JP2011508725A (ja) 2007-11-30 2011-03-17 グラクソスミスクライン・リミテッド・ライアビリティ・カンパニー プロリルヒドロキシラーゼ阻害剤
US8269008B2 (en) 2007-12-03 2012-09-18 Fibrogen, Inc. Oxazolopyridine and isoxazolopyridine derivatives for use in the treatment of HIF-mediated conditions
US20100298324A1 (en) 2007-12-19 2010-11-25 Smith Kline Beecham Corporation Prolyl Hydroxylase Inhibitors
US20110003013A1 (en) 2008-01-04 2011-01-06 Garvan Institute Of Medical Research Method of increasing metabolism
US8952160B2 (en) 2008-01-11 2015-02-10 Fibrogen, Inc. Isothiazole-pyridine derivatives as modulators of HIF (hypoxia inducible factor) activity
CA2716706C (en) * 2008-03-03 2014-02-18 Irm Llc Compounds and compositions as tlr activity modulators
US20090228298A1 (en) * 2008-03-04 2009-09-10 The General Electric Company System and method of morphology feature analysis of physiological data
EP2268143A4 (en) * 2008-03-20 2012-06-27 Forest Lab Holdings Ltd NEW PIPERIDINE DERIVATIVES AS INHIBITORS OF THE STEAROYL COA DESATURASE
AR071997A1 (es) 2008-06-04 2010-07-28 Bristol Myers Squibb Co Forma cristalina de 6-((4s)-2-metil-4-(2-naftil)-1,2,3,4-tetrahidroisoquinolin-7-il)piridazin-3-amina
BRPI0916233A2 (pt) * 2008-07-23 2018-03-13 F.Hoffman-La Roche Ag compostos heterocíclicos antivirais
AU2009290365B2 (en) 2008-09-15 2014-08-14 Kasina Laila Innova Pharmaceuticals Private Limited Anti-cancer drugs and uses relating thereto for metastatic malignant melanoma and other cancers
JP5649584B2 (ja) 2008-11-14 2015-01-07 フィブロジェン インコーポレイテッド Ｈｉｆヒドロキシラーゼ阻害剤としてのチオクロメン誘導体
BRPI1013432B1 (pt) * 2009-03-31 2019-12-17 Kissei Pharmaceutical derivado de indolizina e composição farmacêutica
CA2774039A1 (en) 2009-11-06 2011-05-12 Aerpio Therapeutics Inc. Methods for increasing the stabilization of hypoxia inducible factor-1 alpha
NO2686520T3 (es) 2011-06-06 2018-03-17
MX2013014310A (es) * 2011-06-06 2014-01-23 Akebia Therapeutics Inc Compuestos y composiciones para estabilizar el factor-2 alfa inducible por hipoxia como un metodo para tratar el cancer.
US20130022974A1 (en) 2011-06-17 2013-01-24 The Regents Of The University Of Michigan Dna methylation profiles in cancer
JP6099644B2 (ja) 2011-07-22 2017-03-22 ベイジン ベータ ファーマシューティカルズ カンパニー， リミテッド プロリルヒドロキシラーゼ阻害剤としての化合物の多形体、およびその使用
KR20160061911A (ko) 2013-04-08 2016-06-01 데니스 엠. 브라운 최적하 투여된 화학 화합물의 치료 효과
SG11201509998WA (en) 2013-06-13 2016-01-28 Akebia Therapeutics Inc Compositions and methods for treating anemia
MX2016002014A (es) 2013-08-16 2016-07-21 Ohio State Innovation Foundation Composiciones y metodos para modular la metilacion de dna.
TW201946625A (zh) 2013-11-15 2019-12-16 美商阿克比治療有限公司 {[5-(3-氯苯基)-3-羥基吡啶-2-羰基]胺基}乙酸之固體型式，其組合物及用途
WO2015112831A1 (en) 2014-01-23 2015-07-30 Akebia Therapeutics, Inc. Compositions and methods for treating ocular diseases
WO2016118858A1 (en) 2015-01-23 2016-07-28 Akebia Therapeutics, Inc. Solid forms of 2-(5-(3-fluorophenyl)-3-hydroxypicolinamido)acetic acid, compositions, and uses thereof
EP3270922A4 (en) 2015-03-20 2018-08-01 Akebia Therapeutics Inc. Deuterium-enriched hypoxia-inducible factor prolyl hydroxylase enzyme inhibitors
DK3277270T3 (da) 2015-04-01 2021-12-06 Akebia Therapeutics Inc Sammensætninger og fremgangsmåder til behandling af anæmi
CN112088155A (zh) 2018-05-09 2020-12-15 阿克比治疗有限公司 用于制备2-[[5-(3-氯苯基)-3-羟基吡啶-2-羰基]氨基]乙酸的方法

Also Published As

Publication number Publication date
RU2016139352A (ru) 2018-12-13
NO2686520T3 (es) 2018-03-17
KR102171315B1 (ko) 2020-10-28
JP2014522409A (ja) 2014-09-04
RS56580B1 (sr) 2018-02-28
KR102032864B1 (ko) 2019-10-16
US20210122715A1 (en) 2021-04-29
HRP20211916T1 (hr) 2022-03-18
EP3000808A1 (en) 2016-03-30
EP3683209B1 (en) 2021-11-10
CY1122639T1 (el) 2021-03-12
PL2718265T3 (pl) 2016-04-29
KR20190141805A (ko) 2019-12-24
PT3683209T (pt) 2021-12-15
HUE048044T2 (hu) 2020-05-28
JP2021059573A (ja) 2021-04-15
US20120309977A1 (en) 2012-12-06
SI3000808T1 (en) 2018-02-28
AU2012268426B2 (en) 2017-02-16
JP7039682B2 (ja) 2022-03-22
KR20190031593A (ko) 2019-03-26
AU2012268426A1 (en) 2014-01-09
EP3290404A1 (en) 2018-03-07
CA2838194A1 (en) 2012-12-13
US9776969B2 (en) 2017-10-03
JP6510094B2 (ja) 2019-05-08
US20150361043A1 (en) 2015-12-17
ES2771232T3 (es) 2020-07-06
US20190375713A1 (en) 2019-12-12
ES2559850T3 (es) 2016-02-16
RU2016139352A3 (es) 2020-01-27
RU2013158640A (ru) 2015-07-20
MX337216B (es) 2016-02-18
HRP20200197T1 (hr) 2020-05-15
HUE057571T2 (hu) 2022-05-28
JP6816195B2 (ja) 2021-01-20
DK3683209T3 (da) 2021-12-06
DK3000808T3 (da) 2017-11-27
HUE034975T2 (en) 2018-05-02
HUE026096T2 (en) 2016-05-30
AU2017202414B2 (en) 2018-07-19
AU2020204528B2 (en) 2022-07-14
RS54517B1 (en) 2016-06-30
US20230002323A1 (en) 2023-01-05
CY1119605T1 (el) 2018-04-04
CA3135440A1 (en) 2012-12-13
SMT201600013B (it) 2016-02-25
PT2718265E (pt) 2016-02-15
KR102000485B1 (ko) 2019-07-16
KR102059366B1 (ko) 2019-12-26
PT3000808T (pt) 2017-11-23
ES2647602T3 (es) 2017-12-22
US10246416B2 (en) 2019-04-02
RU2764667C2 (ru) 2022-01-19
MX2013014228A (es) 2014-03-26
AU2018250355A1 (en) 2018-11-08
KR20140037192A (ko) 2014-03-26
CN103717575A (zh) 2014-04-09
EP2718265A4 (en) 2014-11-19
HRP20151416T1 (hr) 2016-03-25
EP2718265A1 (en) 2014-04-16
CA2838194C (en) 2022-01-11
JP6290781B2 (ja) 2018-03-07
HK1216173A1 (zh) 2016-10-21
RS59902B1 (sr) 2020-03-31
US9145366B2 (en) 2015-09-29
JP7284309B2 (ja) 2023-05-30
EP3000808B1 (en) 2017-09-27
HRP20171740T1 (hr) 2018-03-09
HK1196616A1 (zh) 2014-12-19
RU2602083C2 (ru) 2016-11-10
AU2017202414A1 (en) 2017-05-04
LT3290404T (lt) 2020-02-25
ES2900572T3 (es) 2022-03-17
JP2022081597A (ja) 2022-05-31
DK3290404T3 (da) 2020-02-17
KR102293016B1 (ko) 2021-08-26
HK1252109A1 (zh) 2019-05-17
EP2718265B1 (en) 2015-12-16
US11267785B2 (en) 2022-03-08
WO2012170377A1 (en) 2012-12-13
US10738010B2 (en) 2020-08-11
IL229775A (en) 2016-06-30
EP3683209A1 (en) 2020-07-22
DK2718265T3 (en) 2016-01-25
SI2718265T1 (sl) 2016-03-31
CY1124874T1 (el) 2022-11-25
SI3290404T1 (sl) 2020-03-31
AU2018250355B2 (en) 2020-04-09
KR20190032617A (ko) 2019-03-27
PL3683209T3 (pl) 2022-02-21
JP2023103414A (ja) 2023-07-26
CY1117177T1 (el) 2017-04-05
JP2018111697A (ja) 2018-07-19
AU2020204528A1 (en) 2020-07-30
EP4026829A1 (en) 2022-07-13
KR20200121911A (ko) 2020-10-26
SI3683209T1 (sl) 2022-03-31
CN106518759A (zh) 2017-03-22
PL3290404T3 (pl) 2020-06-01
PL3000808T3 (pl) 2018-03-30
JP2019123741A (ja) 2019-07-25
PT3290404T (pt) 2020-02-19
LT3000808T (lt) 2018-01-25
US20170362178A1 (en) 2017-12-21
CN106518759B (zh) 2019-07-30
NZ618570A (en) 2015-07-31
LT3683209T (lt) 2022-01-10
EP3290404B1 (en) 2019-12-11

Similar Documents

Publication Publication Date Title
AU2018250355B2 (en) Process for preparing [(3-hydroxypyridine-2-carbonyl)amino]alkanoic acids, esters and amides
NZ603478A (en) 2 -aminopyridine derivatives useful as inhibitors of atr kinase
MX2018001491A (es) Metodos para la preparacion de acidos biliares y derivados de los mismos.
IN2014KN00929A (es)
WO2011123946A8 (en) Kinase inhibitors and method of treating cancer with same
MX2012002752A (es) Compuestos de heteroarilo como inhibidores de cinasa.
NZ594195A (en) N-acyl anthranilic acid derivative or salt thereof
MX2015005286A (es) Procedimiento para la preparación de derivados del ácido biliar.
TN2014000058A1 (en) A Novel 1,2,3,4-Tetrahydroquinoline Derivative Useful for the Treatment of Diabetes
SG179186A1 (en) Novel compounds effective as xanthine oxidase inhibitors, method for preparing the same, and pharmaceutical composition containing the same
MX2018001145A (es) Métodos para la preparación de ácidos biliares y derivados de los mismos.
EA032972B1 (ru) Гетероциклические карбоновые кислоты в качестве активаторов растворимой гуанилатциклазы
MX2012002758A (es) Pirazinil-piridinas utiles para el tratamiento de enfermedades proliferativas.
IN2014CN02188A (es)
NZ610378A (en) Lipoyl compounds and their use for treating ischemic injury
FR2972452B1 (fr) Procede de preparation du difluoroacetonitrile et de ses derives
MX363986B (es) Metodo para producir carboxamidas.
MX2014002448A (es) Reduccion de acidos fosforosos organicos.
SI2247573T1 (sl) Soli ogljikove in Ĺľveplove kisline in 3-(2,2,2-trimetilhidrazin) propionat estrov ter njihova uporaba pri pripravi 3-(2,2,2-trimetilhidrazin) propionat dihidrata
MX2012001722A (es) Nuevo procedimiento de sintesis de la ivabradina y de sus sales de adicion a un acido farmaceuticamente aceptable.
AU2012313971A8 (en) 5 - benzylaminomethyl - 6 - aminopyrazolo [3, 4 -b] pyridine derivatives as cholesteryl ester -transfer protein (CETP) inhibitors useful for the treatment of atherosclerosis
SG179153A1 (en) Pharmaceutical combination for treating tumor
MX2011008810A (es) Metodo para fabricar un producto de fermentacion que contiene propionato y acetato que comprende un paso de eliminacion de compuestos relacionados con carbonato.
IN2015DN00659A (es)
IN2013MU03423A (es)